Based on the key indicators related to Emergent Biosolutions' liquidity, profitability, solvency, and operating efficiency, Emergent Biosolutions is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August. At this time, Emergent Biosolutions' Long Term Debt is comparatively stable compared to the past year. Common Stock Total Equity is likely to gain to about 120.8 K in 2025, whereas Short and Long Term Debt Total is likely to drop slightly above 383.1 M in 2025. Key indicators impacting Emergent Biosolutions' financial strength include:
Investors should never underestimate Emergent Biosolutions' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Emergent Biosolutions' cash flow, debt, and profitability to make informed and accurate decisions about investing in Emergent Biosolutions.
Understanding current and past Emergent Biosolutions Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Emergent Biosolutions' financial statements are interrelated, with each one affecting the others. For example, an increase in Emergent Biosolutions' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Emergent Biosolutions' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Emergent Biosolutions. Check Emergent Biosolutions' Beneish M Score to see the likelihood of Emergent Biosolutions' management manipulating its earnings.
Emergent Biosolutions Stock Summary
Emergent Biosolutions competes with Elanco Animal, SIGA Technologies, Esperion Therapeutics, Vir Biotechnology, and Quidel. Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats in the United States. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. Emergent Biosolutions operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 2416 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Emergent Biosolutions Key Income Statement Accounts
The reason investors look at the income statement is to determine what Emergent Biosolutions' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Emergent Biosolutions's current stock value. Our valuation model uses many indicators to compare Emergent Biosolutions value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Emergent Biosolutions competition to find correlations between indicators driving Emergent Biosolutions's intrinsic value. More Info.
Emergent Biosolutions is rated # 4 in return on equity category among its peers. It also is rated # 4 in return on asset category among its peers . At this time, Emergent Biosolutions' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Emergent Biosolutions by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Emergent Biosolutions Systematic Risk
Emergent Biosolutions' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Emergent Biosolutions volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was nine with a total number of output elements of fifty-two. The Beta measures systematic risk based on how returns on Emergent Biosolutions correlated with the market. If Beta is less than 0 Emergent Biosolutions generally moves in the opposite direction as compared to the market. If Emergent Biosolutions Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Emergent Biosolutions is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Emergent Biosolutions is generally in the same direction as the market. If Beta > 1 Emergent Biosolutions moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Emergent Biosolutions Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Emergent Biosolutions' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Emergent Biosolutions growth as a starting point in their analysis.
Emergent Biosolutions July 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Emergent Biosolutions help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Emergent Biosolutions. We use our internally-developed statistical techniques to arrive at the intrinsic value of Emergent Biosolutions based on widely used predictive technical indicators. In general, we focus on analyzing Emergent Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Emergent Biosolutions's daily price indicators and compare them against related drivers.
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.